A prospective study on the early evaluation of response to androgen receptor-targeted agents with 11C-Choline, 68Ga-PSMA, and 18F-FACBC PET in metastatic castration-resistant prostate cancer: a single-center experience
-
Published:2024-05
Issue:5
Volume:9
Page:103448
-
ISSN:2059-7029
-
Container-title:ESMO Open
-
language:en
-
Short-container-title:ESMO Open
Author:
Mollica V.ORCID,
Marchetti A.ORCID,
Fraccascia N.,
Nanni C.,
Tabacchi E.,
Malizia C.,
Argalia G.ORCID,
Rosellini M.,
Tassinari E.ORCID,
Paccapelo A.,
Fanti S.,
Massari F.ORCID
Reference27 articles.
1. Cancer statistics, 2023;Siegel;CA Cancer J Clin,2023
2. Prostate cancer and novel pharmacological treatment options-what’s new for 2022?;Marchetti;Expert Rev Clin Pharmacol,2023
3. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study;Fizazi;Lancet Oncol,2012
4. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study;Ryan;Lancet Oncol,2015
5. Increased survival with enzalutamide in prostate cancer after chemotherapy;Scher;N Engl J Med,2012